Across TCGA pan-cancer cohorts, IPO9 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IPO9 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IPO9 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IPO9 expression acts as an unfavorable survival marker.

HNSC, PDAC, and CCRCC are the cancer types where IPO9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.709	0.932	.006	49	view →
PDAC	OS	Tertile	III,IV	0.542	0.966	.003	29	view →
CCRCC	DFS	Tertile	IV	0.188	0.961	.024	12	view →
OV	DFS	Median	All	0.874	1.000	.047	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: IPO9 tumor-vs-normal RNA expression · all IPO9 data types